Ashwani Verma
Stock Analyst at UBS
(4.10)
# 509
Out of 5,139 analysts
105
Total ratings
56%
Success rate
12.59%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $223 → $215 | $161.42 | +33.19% | 1 | Jan 6, 2026 | |
| UTHR United Therapeutics | Maintains: Buy | $600 → $645 | $464.93 | +38.73% | 11 | Jan 6, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $163 → $248 | $177.27 | +39.90% | 6 | Jan 6, 2026 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $40 | $25.99 | +53.91% | 9 | Jan 6, 2026 | |
| CORT Corcept Therapeutics | Initiates: Neutral | $95 | $34.73 | +173.54% | 1 | Dec 16, 2025 | |
| LEGN Legend Biotech | Maintains: Buy | $54 → $48 | $22.14 | +116.80% | 4 | Dec 8, 2025 | |
| BHVN Biohaven | Downgrades: Neutral | $26 → $11 | $13.14 | -16.29% | 5 | Nov 26, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $163 → $188 | $169.41 | +10.97% | 7 | Nov 24, 2025 | |
| ALVO Alvotech | Maintains: Buy | $13 → $10 | $4.92 | +103.25% | 1 | Nov 18, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $195 → $220 | $214.35 | +2.64% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $40 | $43.96 | -9.01% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $21.48 | -6.89% | 4 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $43 | $36.22 | +18.72% | 3 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $188 → $195 | $132.39 | +47.29% | 10 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $26 | $31.76 | -18.14% | 10 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $68 | $106.21 | -35.98% | 2 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $26.27 | -31.48% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $33 → $42 | $31.63 | +32.79% | 5 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $47 → $41 | $62.58 | -34.48% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.60 | -34.38% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $68.94 | +65.36% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $39.55 | -29.20% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $191.04 | -96.34% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $12.86 | -6.69% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.39 | +979.14% | 1 | Oct 11, 2022 |
Insmed
Jan 6, 2026
Maintains: Buy
Price Target: $223 → $215
Current: $161.42
Upside: +33.19%
United Therapeutics
Jan 6, 2026
Maintains: Buy
Price Target: $600 → $645
Current: $464.93
Upside: +38.73%
Axsome Therapeutics
Jan 6, 2026
Maintains: Buy
Price Target: $163 → $248
Current: $177.27
Upside: +39.90%
ACADIA Pharmaceuticals
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $25.99
Upside: +53.91%
Corcept Therapeutics
Dec 16, 2025
Initiates: Neutral
Price Target: $95
Current: $34.73
Upside: +173.54%
Legend Biotech
Dec 8, 2025
Maintains: Buy
Price Target: $54 → $48
Current: $22.14
Upside: +116.80%
Biohaven
Nov 26, 2025
Downgrades: Neutral
Price Target: $26 → $11
Current: $13.14
Upside: -16.29%
Jazz Pharmaceuticals
Nov 24, 2025
Downgrades: Neutral
Price Target: $163 → $188
Current: $169.41
Upside: +10.97%
Alvotech
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $4.92
Upside: +103.25%
AbbVie
Nov 7, 2025
Maintains: Neutral
Price Target: $195 → $220
Current: $214.35
Upside: +2.64%
Nov 6, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $43.96
Upside: -9.01%
Oct 28, 2025
Downgrades: Neutral
Price Target: $20
Current: $21.48
Upside: -6.89%
Oct 15, 2025
Maintains: Buy
Price Target: $50 → $43
Current: $36.22
Upside: +18.72%
Oct 9, 2025
Maintains: Buy
Price Target: $188 → $195
Current: $132.39
Upside: +47.29%
Sep 24, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $31.76
Upside: -18.14%
Jul 30, 2025
Maintains: Neutral
Price Target: $62 → $68
Current: $106.21
Upside: -35.98%
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $26.27
Upside: -31.48%
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $31.63
Upside: +32.79%
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $62.58
Upside: -34.48%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.60
Upside: -34.38%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $68.94
Upside: +65.36%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $39.55
Upside: -29.20%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $191.04
Upside: -96.34%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $12.86
Upside: -6.69%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $1.39
Upside: +979.14%